ciltacabtagene autoleucel,Pomalidomide,Bortezomib,Dexamethasone,Daratumumab
Janssen
['lenalidomide', ' lena', 'cilta-cel', 'cartitude-4', 'mmsm', 'cartitude']
aa11: change of soc: cartitude-4: cilta-cel vs pvd or dpd in lenalidomide-refractory mm
- rct/phase iii
- early relapse mm
- high risk cyto: 60%, without 1q 35%
- triple class rrmm: 15% #mmsm #myeloma #medtwitter #meded #asco23 #usmirc 
Associate Professor,Plasma Cell disorder program Director, Division of HMCT/University of Kansas Medical Center, no COI, #USMIRC Founder, #mmsm @KUMedCenter